来自官方财务报表的收入、利润与现金流历史。
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD.
| 利润表 | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| 总收入 | $0M | $0M | $0M | $0M | $0M |
| 毛利 | ($1M) | ($1M) | $0M | — | — |
| 毛利率% | — | — | — | — | — |
| 营业利润（EBIT） | ($305M) | ($286M) | ($217M) | ($93M) | ($31M) |
| 营业利润率% | — | — | — | — | — |
| 净利 | ($275M) | ($256M) | ($182M) | ($84M) | ($40M) |
| 净利润率 % | — | — | — | — | — |
| EBITDA | ($273M) | ($254M) | ($182M) | ($75M) | ($40M) |
| 每股收益（EPS） | $-4.44 | $-4.22 | $-3.30 | $-1.66 | $-0.79 |
| 已发行股数 (M) | 70M | 61M | 55M | 51M | 51M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 APGE 交互式查看器。 /companies/us/APGE
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms